Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus Ipilimumab versus Sunitinib in Advanced or Metastatic Renal Cell Carcinoma
2023-504761-23-00Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 22
01
Overview
Phase 3, randomised, open-label trial in renal cell carcinoma (RCC) comparing Nivolumab plus Ipilimumab with Sunitinib monotherapy (2 arms). Primary endpoints: overall survival and progression-free survival. Started Aug 2023; status: completed.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2023-504761-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504761-23-00.